Abstract
Drugs interact with their targets in different ways. A diversity of modeling approaches exists to describe the combination effects of two drugs. We investigate several combination effect terms (CET) regarding their underlying mechanism based on drug-receptor binding kinetics, empirical and statistical summation principles and indirect response models. A list with properties is provided and the interrelationship of the CETs is analyzed. A method is presented to calculate the optimal drug concentration pair to produce the half-maximal combination effect. This work provides a comprehensive overview of typically applied CETs and should shed light into the question as to which CET is appropriate for application in pharmacokinetic/pharmacodynamic models to describe a specific drug–drug interaction mechanism.
Similar content being viewed by others
References
Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31(5):510–518
Hill AV (1910) The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 40:iv–vii
Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P (2008) The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol 22(6):633–648
Wagner JG (1968) Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20(2):173–201
Michaelis L, Menten ML (1913) Die Kinetic der Invertinwirkung. Biochem Z 49:333–369
Ariens EJ, Van Rossum JM, Simonis AM (1957) Affinity, intrinsic activity and drug interactions. Pharmacol Rev 9(2):218–236
Ariens EJ, Simonis AM (1964) A molecular basis for drug action. J Pharm Pharmacol 16:137–157
Ariens EJ, Simonis AM (1964) A molecular basis for durg action. The interaction of one or more drugs with different receptors. J Pharm Pharmacol 16:289–312
Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 50(17):5318–5327
Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko WJ (2004) Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn 31(5):345–380
Kong M, Lee JJ (2006) A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics 62(4):986–995
Twarog NR, Stewart E, Hammill CV, Shelat A A (2016) BRAID: a unifying paradigm for the analysis of combined drug action. Sci Rep 6:25523
Minto CF, Schnider TW, Short TG, Gregg KM, Gentilini A, Shafer SL (2000) Response surface model for anesthetic drug interactions. Anesthesiology 92(6):1603–1616
Chakraborty A, Jusko WJ (2002) Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. J Pharm Sci 91(5):1334–1342
Koch G, Walz A, Lahu G, Schropp J (2009) Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 36(2):179–197
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ (2013) Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J 15(1):78–84
Koch G, Schropp J (2013) Mathematical concepts in pharmacokinetics and pharmacodynamics with application to tumor Growth. In: Kloeden EP, Pötzsche C (eds) Nonautonomous dynamical systems in the life sciences. Springer International Publishing, Cham, pp 225–250
Mould DR, Walz AC, Lave T, Gibbs JP, Frame B (2015) Developing exposure/response models for anticancer drug treatment: special considerations. CPT Pharmacometrics Syst Pharmacol 4(1):e00016
Miao X, Koch G, Straubinger RM, Jusko WJ (2016) Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemother Pharmacol 77(1):181–193
Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, Gonen M, Schwartz GK, Kern SE, Zabludoff S, Brassil PJ (2010) Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemother Pharmacol 66(2):245–254
Bonate PL, Howard DR (2011) Pharmacokinetics in drug development: advances and applications, vol 3. Springer, New York
Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD (2013) Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS ONE 8(3):e58089
Choo EF, Ng CM, Berry L, Belvin M, Lewin-Koh N, Merchant M, Salphati L (2013) PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3 K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol 71(1):133–143
Li M, Li H, Cheng X, Wang X, Li L, Zhou T, Lu W (2013) Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine. Pharm Res 30(5):1400–1408
Wu Q, Li MY, Li HQ, Deng CH, Li L, Zhou TY, Lu W (2013) Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model. Acta Pharmacol Sin 34(11):1427–1436
Zhu X, Straubinger RM, Jusko WJ (2015) Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn 42(5):477–496
Hamed SS, Roth CM (2011) Mathematical modeling to distinguish cell cycle arrest and cell killing in chemotherapeutic concentration response curves. J Pharmacokinet Pharmacodyn 38(3):385–403
Schättler H, Ledzewicz U (2015) Optimal control for mathematical models of cancer therapies: an application of geometric methods. Interdisciplinary applied mathematics, vol 42. Springer, New York
Banks HT (1975) Modeling and control in the biomedical sciences. Lecture notes in biomathematics, vol 6. Springer, Berlin
Yan X, Chen Y, Krzyzanski W (2012) Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn 39(5):543–560
Oosterhuis B, van Boxtel CJ (1988) Kinetics of drug effects in man. Ther Drug Monit 10(2):121–132
Milad MA, Ludwig EA, Anne S, Middleton E Jr, Jusko WJ (1994) Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. J Pharmacokinet Biopharm 22(6):469–480
Kenakin T (2009) A pharmacology primer: theory application and methods. Elsevier, Burlington
Berenbaum MC (1989) What is synergy? Pharmacol Rev 41(2):93–141
Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47(2):331–385
Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681
Tang J, Wennerberg K, Aittokallio T (2015) What is synergy? The Saariselka agreement revisited. Front Pharmacol 6:181
Loewe S (1928) Die quantitativen Probleme der Pharmakologie. Ergebnisse der Physiologie 27(1):47–187
Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2(9):458–466
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55
Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26:585–615
Jonker DM, Visser SA, van der Graaf PH, Voskuyl RA, Danhof M (2005) Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther 106(1):1–18
Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21(4):457–478
Wetzler M, Earp JC, Brady MT, Keng MK, Jusko WJ (2007) Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity–pharmacodynamic drug-drug interaction modeling. Clin Cancer Res 13(7):2261–2270
Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression: a critical review. Clin Exp Immuno 28(1):1–18
Gabrielsson J, Gibbons FD, Peletier LA (2016) Mixture dynamics: combination therapy in oncology. Eur J Pharm Sci 88:133–146
Jeleazcov C, Ihmsen H, Schmidt J, Ammon C, Schwilden H, Schuttler J, Fechner J (2008) Pharmacodynamic modelling of the bispectral index response to propofol-based anaesthesia during general surgery in children. Br J Anaesth 100(4):509–516
Acknowledgments
This work was supported by the National Institutes of Health [GM 24211], the National Research Fund, Luxembourg, and co-funded under the Marie Curie Actions of the European Commission (FP7-COFUND).
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix 1: Drug receptor binding kinetics
General derivation
From the conservation of receptors and complexes Eq. (11) we obtain the receptor representation
Rewriting the complexes Eqs. (8)–(10) with Eq. (51)
Pseudo steady-state analysis of Eqs. (52)–(54) for the complexes and substituting Eq. (54) into Eq. (52) then leads to
With \(K_{DA} = \frac{{k_{offA} }}{{k_{onA} }}\) and \(K_{DB} = \frac{{k_{offB} }}{{k_{onB} }}\) we obtain
Dividing Eq. (55) by \(K_{DA}\) and Eqs. (56)–(57) by \(K_{DB}\) we obtain the matrix notation Eq. (12)
We apply Cramer’s rule and obtain
Note that \(M_{0}\) is strictly positive and \(M_{i}\), \(i = 1,2,3\) are non-negative for \(C_{A} ,C_{B} \ge 0\). The complexes then read
Inserting Eqs. (58)–(60) in Eq. (13) then results in Eq. (14).
Appendix 2: Competitive CET
Derivation
Applying Cramer’s rule to Eq. (15) gives
The complexes then read
Inserting Eqs. (61)-(62) in Eq. (16) then results in Eq. (17).
Maximal effect
Diagonality
If drug \(A\) equals drug \(B\), we have
Agonistic-antagonist
For an antagonistic drug \(B\) we have \(e\left( {C_{B} } \right) = 0\) for \(C_{B} \ge 0\) and therefore \(E_{maxB} = 0\). Hence, we obtain with Eq. (18)
Appendix 3: Uncompetitive CET
Derivation
The determinants for Cramer’s rule applied to Eq. (19) are
The complexes then read
Inserting Eqs. (63)–(64) in Eq. (20) then results in Eq. (21).
Appendix 4: Loewe CET
Derivation
Rearranging Eq. (27) with respect to \(DC_{X}\) gives
Substituting Eq. (65) in Eq. (26) gives Eq. (28). Equation (28) can be written with \(\gamma_{A} = \gamma_{B} = \gamma\) as
resulting in
Rearranging of Eq. (66) gives the Loewe CET Eq. (29).
Appendix 5: Bliss CET
Diagonality
We have
Hence, the diagonality condition is satisfied with \(\sigma = \frac{1}{4}\).
Appendix 6: Greco and Summation CET
Diagonality of the Greco CET
For \(\gamma_{A} = \gamma_{B} = 1\) we obtain with Eq. (37)
and the diagonality condition is fulfilled with \(\sigma = \frac{\alpha }{4}\).
Diagonality of the summation CET
For equal drugs we can compute
Thus, \(E^{Sum} \left( {\frac{{C_{A} }}{2},\frac{{C_{A} }}{2}} \right)\) cannot be written in the form assumed in the diagonality condition. To see the last inequality please note that with
we have
Since \(e^{{\prime }} \left( x \right) > 0\) and \(e'\) monotone decreasing, \(f_{1} \left( x \right) > f_{2} (x)\), \(x > 0\) follows and with \(x = \frac{{C_{A} }}{2}\) the inequality.
Appendix 7: IDR CETs
Equivalent formulation for the inhibitory CET
To demonstrate the equivalence of Eq. (40) with Eqs. (41)–(42), we have to show
The denominator from Eq. (42) can be written as
and the numerator reads
Hence, we obtain
Diagonality of the stimulation CET
If drug \(A\) equals drug \(B\), we have
Hence, \(E^{Stim} \left( {\frac{{C_{A} }}{2},\frac{{C_{A} }}{2}} \right)\) cannot be written in form of a single drug effect term. With similar calculations we obtain the same conclusion for \(I^{IDR}\).
Appendix 8: Relationships
To simplify the notation we set
For \(E_{maxA} ,E_{maxB} ,\gamma_{A} ,\gamma_{B} > 0\), Eq. (45) follows from
In the case of \(E_{maxA} = E_{maxB} = E_{max} > 0\) and \(\gamma_{A} ,\gamma_{B} > 0\) we have
where \(\eta > 0\) indicates existence of the multiplicative term \(xy\). In Eqs. (46)–(47) the last inequality is obvious. Evaluation of Eq. (67) at \(\eta = 1\) and Eq. (68) at \(\eta = 1\) yields Eq. (46). In the case of \(E_{maxA} = E_{maxB} = E_{max}\) and \(\gamma_{A} = \gamma_{B} = 1\) we obtain Eq. (47) with evaluation of Eq. (67) at \(\eta \in (0,1)\), and \(\eta = 1\) in Eq. (68).
Appendix 9: Optimal concentration pair for half-maximal combination effect
In the following calculation we assume \(\gamma_{A} = \gamma_{B} = \gamma = 1\) and set
Competitive CET
We assume \(E_{maxB} = E_{maxA} = E_{max} > 0\). Using Eq. (18) by definition of the half maximal effect curve we have to solve
which is equivalent to
This leads to
and the CET specific function for the half-maximal effect curve reads
The next step is to investigate the \(CI\) values on the half-maximal effect curve which is due to Loewe Additivity Eq. (49) given by the objective function
with its specific \(\varphi\) under the constraints \(x \ge 0, \varphi \left( x \right) \ge 0\). In case of the competitive CET we obtain
which gives the solution \(CI^{Loewe} = 1\) and optimal concentration pairs are given by
Greco CET
With Eq. (69) we obtain from Eq. (37) with \(E = \frac{{E_{max} }}{2}\)
resulting in
With Eq. (71) the objective function reads
and we calculate
if and only if
This leads to
Using
we obtain
For \(\alpha = 0\) we have \(h_{Greco} \left( x \right) = x + \varphi_{Greco} \left( x \right) = 1\) which leads to \(CI^{Loewe} = 1\).
Bliss CET
Using Eq. (33) we obtain
which is equivalent to
This leads to
According to Eq. (50) and Eq. (73) the objective function reads
We obtain the solution
with \(CI^{Bliss} = 1\).
Summation CET
With Eq. (69) and \(E_{maxA} = E_{maxB} = E_{max}\) we obtain from Eq. (38)
Rearranging with respect to \(y\)
results in
We set with Eq. (50)
and obtain
and therefore
Hence, we obtain
and the optimal pair is
with \(CI^{Bliss} = x + y + 1 = 3\). Please note that a classification of the area of antagonistic, additive, or synergistic does not hold since the objective functions Eqs. (49), (50) defining the classifications have to be scaled appropriately, if \(E_{maxAB} > \hbox{max} \left\{ {E_{maxA} ,E_{maxB} } \right\}\).
Rights and permissions
About this article
Cite this article
Koch, G., Schropp, J. & Jusko, W.J. Assessment of non-linear combination effect terms for drug–drug interactions. J Pharmacokinet Pharmacodyn 43, 461–479 (2016). https://doi.org/10.1007/s10928-016-9490-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-016-9490-0